Literature DB >> 18690118

Dopamine and opioid gene variants are associated with increased smoking reward and reinforcement owing to negative mood.

Kenneth A Perkins1, Caryn Lerman, Amy Grottenthaler, Melinda M Ciccocioppo, Melissa Milanak, Cynthia A Conklin, Andrew W Bergen, Neal L Benowitz.   

Abstract

Negative mood increases smoking reinforcement and risk of relapse. We explored associations of gene variants in the dopamine, opioid, and serotonin pathways with smoking reward ('liking') and reinforcement (latency to first puff and total puffs) as a function of negative mood and expected versus actual nicotine content of the cigarette. Smokers of European ancestry (n=72) were randomized to one of four groups in a 2x2 balanced placebo design, corresponding with manipulation of actual (0.6 vs. 0.05 mg) and expected (told nicotine and told denicotinized) nicotine 'dose' in cigarettes during each of two sessions (negative vs. positive mood induction). Following mood induction and expectancy instructions, they sampled and rated the assigned cigarette, and then smoked additional cigarettes ad lib during continued mood induction. The increase in smoking amount owing to negative mood was associated with: dopamine D2 receptor (DRD2) C957T (CC>TT or CT), SLC6A3 (presence of 9 repeat>absence of 9), and among those given a nicotine cigarette, DRD4 (presence of 7 repeat>absence of 7) and DRD2/ANKK1 TaqIA (TT or CT>CC). SLC6A3, and DRD2/ANKK1 TaqIA were also associated with smoking reward and smoking latency. OPRM1 (AA>AG or GG) was associated with smoking reward, but SLC6A4 variable number tandem repeat was unrelated to any of these measures. These results warrant replication but provide the first evidence for genetic associations with the acute increase in smoking reward and reinforcement owing to negative mood.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18690118      PMCID: PMC2717609          DOI: 10.1097/FBP.0b013e32830c367c

Source DB:  PubMed          Journal:  Behav Pharmacol        ISSN: 0955-8810            Impact factor:   2.293


  49 in total

1.  Role of functional genetic variation in the dopamine D2 receptor (DRD2) in response to bupropion and nicotine replacement therapy for tobacco dependence: results of two randomized clinical trials.

Authors:  Caryn Lerman; Christopher Jepson; E Paul Wileyto; Leonard H Epstein; Margaret Rukstalis; Freda Patterson; Vyga Kaufmann; Stephanie Restine; Larry Hawk; Ray Niaura; Wade Berrettini
Journal:  Neuropsychopharmacology       Date:  2006-01       Impact factor: 7.853

2.  Allelic expression imbalance of human mu opioid receptor (OPRM1) caused by variant A118G.

Authors:  Ying Zhang; Danxin Wang; Andrew D Johnson; Audrey C Papp; Wolfgang Sadée
Journal:  J Biol Chem       Date:  2005-07-26       Impact factor: 5.157

Review 3.  Genetics and smoking cessation improving outcomes in smokers at risk.

Authors:  Caryn E Lerman; Robert A Schnoll; Marcus R Munafò
Journal:  Am J Prev Med       Date:  2007-12       Impact factor: 5.043

4.  Dissociating the nicotine and airway sensory effects of smoking.

Authors:  E C Westman; F M Behm; J E Rose
Journal:  Pharmacol Biochem Behav       Date:  1996-02       Impact factor: 3.533

5.  Cigarette smoking during anxiety-provoking and monotonous tasks.

Authors:  J E Rose; S Ananda; M E Jarvik
Journal:  Addict Behav       Date:  1983       Impact factor: 3.913

6.  Effects of nicotine dose, instructional set, and outcome expectancies on the subjective effects of smoking in the presence of a stressor.

Authors:  Laura M Juliano; Thomas H Brandon
Journal:  J Abnorm Psychol       Date:  2002-02

Review 7.  Nesbitt's Paradox resolved? Stress and arousal modulation during cigarette smoking.

Authors:  A C Parrott
Journal:  Addiction       Date:  1998-01       Impact factor: 6.526

8.  Stress-induced cigarette craving: effects of the DRD2 TaqI RFLP and SLC6A3 VNTR polymorphisms.

Authors:  J Erblich; C Lerman; D W Self; G A Diaz; D H Bovbjerg
Journal:  Pharmacogenomics J       Date:  2004       Impact factor: 3.550

9.  Interacting effects of genetic predisposition and depression on adolescent smoking progression.

Authors:  Janet Audrain-McGovern; Caryn Lerman; E Paul Wileyto; Daniel Rodriguez; Peter G Shields
Journal:  Am J Psychiatry       Date:  2004-07       Impact factor: 18.112

10.  The influence of instructions and nicotine dose on the subjective and reinforcing effects of smoking.

Authors:  Kenneth A Perkins; Lynette Jacobs; Melinda Ciccocioppo; Cynthia Conklin; Michael Sayette; Anthony Caggiula
Journal:  Exp Clin Psychopharmacol       Date:  2004-05       Impact factor: 3.157

View more
  41 in total

Review 1.  Addiction as a systems failure: focus on adolescence and smoking.

Authors:  Ruben D Baler; Nora D Volkow
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2011-01-26       Impact factor: 8.829

Review 2.  Nicotine reduction revisited: science and future directions.

Authors:  Dorothy K Hatsukami; Kenneth A Perkins; Mark G Lesage; David L Ashley; Jack E Henningfield; Neal L Benowitz; Cathy L Backinger; Mitch Zeller
Journal:  Tob Control       Date:  2010-10       Impact factor: 7.552

3.  Severity of tobacco abstinence symptoms varies by time of day.

Authors:  Kenneth A Perkins; Jessica Briski; Carolyn Fonte; John Scott; Caryn Lerman
Journal:  Nicotine Tob Res       Date:  2009-01-27       Impact factor: 4.244

Review 4.  A review of human drug self-administration procedures.

Authors:  Jermaine D Jones; Sandra D Comer
Journal:  Behav Pharmacol       Date:  2013-09       Impact factor: 2.293

Review 5.  Pharmacogenetics of OPRM1.

Authors:  Richard C Crist; Wade H Berrettini
Journal:  Pharmacol Biochem Behav       Date:  2013-11-05       Impact factor: 3.533

Review 6.  A review of pharmacogenetic studies of substance-related disorders.

Authors:  Jermaine D Jones; Sandra D Comer
Journal:  Drug Alcohol Depend       Date:  2015-03-18       Impact factor: 4.492

7.  Nicotine withdrawal sensitivity, linkage to chr6q26, and association of OPRM1 SNPs in the SMOking in FAMilies (SMOFAM) sample.

Authors:  Jill Hardin; Yungang He; Harold S Javitz; Jennifer Wessel; Ruth E Krasnow; Elizabeth Tildesley; Hyman Hops; Gary E Swan; Andrew W Bergen
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2009-12       Impact factor: 4.254

Review 8.  OPRM1 SNP (A118G): involvement in disease development, treatment response, and animal models.

Authors:  Stephen D Mague; Julie A Blendy
Journal:  Drug Alcohol Depend       Date:  2010-01-13       Impact factor: 4.492

9.  GLOBAL OPIOID EPIDEMIC: DOOMED TO FAIL WITHOUT GENETICALLY BASED PRECISION ADDICTION MEDICINE (PAM): LESSONS LEARNED FROM AMERICA.

Authors:  Kenneth Blum; Edward J Modestino; Marjorie C Gondré-Lewis; Jennifer Neary; David Siwicki; Mary Hauser; Debmalya Barh; Bruce Steinberg; Rajendra D Badgaiyan
Journal:  Precis Med (Bangalore)       Date:  2017-11-18

Review 10.  Neurogenetics of dopaminergic receptor supersensitivity in activation of brain reward circuitry and relapse: proposing "deprivation-amplification relapse therapy" (DART).

Authors:  Kenneth Blum; Thomas J H Chen; B William Downs; Abdalla Bowirrat; Roger L Waite; Eric R Braverman; Margaret Madigan; Marlene Oscar-Berman; Nicholas DiNubile; Eric Stice; John Giordano; Siobhan Morse; Mark Gold
Journal:  Postgrad Med       Date:  2009-11       Impact factor: 3.840

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.